- Home
- BIIB vs TROW Comparison
BIIB vs TROW Comparison
Compare BIIB & TROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- TROW
- Stock Information
- Founded
- BIIB 1978
- TROW 1937
- Country
- BIIB United States
- TROW United States
- Employees
- BIIB N/A
- TROW N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- TROW Investment Bankers/Brokers/Service
- Sector
- BIIB Health Care
- TROW Finance
- Exchange
- BIIB Nasdaq
- TROW Nasdaq
- Market Cap
- BIIB 25.1B
- TROW 26.2B
- IPO Year
- BIIB 1991
- TROW N/A
- Fundamental
- Price
- BIIB $149.02
- TROW $117.07
- Analyst Decision
- BIIB Buy
- TROW Sell
- Analyst Count
- BIIB 26
- TROW 12
- Target Price
- BIIB $248.00
- TROW $116.25
- AVG Volume (30 Days)
- BIIB 1.6M
- TROW 1.5M
- Earning Date
- BIIB 02-11-2025
- TROW 02-06-2025
- Dividend Yield
- BIIB N/A
- TROW 4.24%
- EPS Growth
- BIIB 10.05
- TROW 30.16
- EPS
- BIIB 11.06
- TROW 9.13
- Revenue
- BIIB $9,607,500,000.00
- TROW $6,911,100,000.00
- Revenue This Year
- BIIB N/A
- TROW $13.10
- Revenue Next Year
- BIIB N/A
- TROW $5.46
- P/E Ratio
- BIIB $13.47
- TROW $12.82
- Revenue Growth
- BIIB N/A
- TROW 8.96
- 52 Week Low
- BIIB $145.07
- TROW $100.49
- 52 Week High
- BIIB $268.30
- TROW $125.81
- Technical
- Relative Strength Index (RSI)
- BIIB 32.44
- TROW 45.43
- Support Level
- BIIB $145.07
- TROW $112.11
- Resistance Level
- BIIB $149.92
- TROW $116.77
- Average True Range (ATR)
- BIIB 3.81
- TROW 2.20
- MACD
- BIIB 0.05
- TROW -0.94
- Stochastic Oscillator
- BIIB 22.51
- TROW 36.20
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About TROW T. Rowe Price Group Inc.
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load us and international stock, hybrid, bond, and money market funds. At the end of August 2024, the firm had $1.612 trillion in managed assets, composed of equity (51%), balanced (34%), fixed-income and money market (12%), and alternative (3%) offerings. Approximately two thirds of managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a us-based asset manager, deriving less than 10% of its AUM from overseas.